Is etodolac the same medication as ketorolac?

No, Etodolac and Ketorolac Are Distinct Medications

Etodolac and ketorolac are two different nonsteroidal anti-inflammatory drugs (NSAIDs) with distinct chemical structures, pharmacokinetic properties, and clinical applications—they are not the same medication and should not be used interchangeably.

Key Differences

Chemical Structure and Classification

• Etodolac is a member of the pyranocarboxylic acid group of NSAIDs, with the chemical formula C₁₇H₂₁NO₃ 1
• Ketorolac belongs to a different NSAID class entirely
• Both inhibit COX-1 and COX-2 enzymes but through different molecular mechanisms 2, 1

Mechanism and Pharmacology

While both drugs work by inhibiting prostaglandin synthesis through COX enzyme inhibition, their pharmacokinetic profiles differ significantly:

• Etodolac:

  • Oral bioavailability >80% 1
  • Peak concentrations reached in 80±30 minutes 1
  • Terminal half-life of 6.4 hours 1

  • 99% protein bound 1

  • Extensively metabolized in the liver 1

• Ketorolac:

  • Rapid onset (1-2 minutes IV, 15-30 minutes IM) 3
  • Available in both parenteral and oral formulations
  • Ketorolac also has reported analgesic mechanisms involving local nitric oxide synthesis 2

Clinical Applications and Dosing

Etodolac 4:

• Typical dosing: 200-400 mg three times daily orally
• Extended release: 600 mg daily
• Primarily used for chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis

Ketorolac 3, 5:

• Acute pain management: 60 mg IM every 15-30 minutes (max 120 mg/day)
• Treatment duration limited to 5 days maximum due to toxicity concerns 3
• Used for acute postoperative pain, not chronic conditions

Safety Profile Differences

Both drugs share typical NSAID adverse effects (GI bleeding, renal dysfunction), but with important distinctions:

Ketorolac-specific concerns 2:

• Higher risk of acute kidney injury, particularly in:
  • Infants <6 months
  • Patients with preexisting renal dysfunction
  • Concomitant aspirin use
  • Single-ventricle palliation patients
• Associated with increased bleeding risk
• Should be used with extreme caution in vulnerable populations

Etodolac 4:

• Studies suggest potentially lower incidence of serious GI toxicity compared to other NSAIDs 6
• Standard NSAID precautions apply for renal, cardiovascular, and GI risks

Comparative Efficacy Data

Direct comparison studies show these are not equivalent:

• In endodontic pain control, ketorolac 10 mg significantly outperformed etodolac 400 mg (VAS scores 0.42±0.69 vs 2.68±2.29, P=0.001) 7
• This demonstrates they have different potencies and cannot be substituted dose-for-dose

Clinical Bottom Line

These medications should never be confused or substituted for one another. Ketorolac is reserved for short-term acute pain management (≤5 days) with careful patient selection, while etodolac is used for longer-term inflammatory conditions. The choice between them depends on:

• Duration of therapy needed: Ketorolac only for acute (<5 days); etodolac for chronic use
• Route of administration required: Ketorolac available IV/IM; etodolac oral only
• Patient risk factors: Ketorolac has stricter contraindications for renal dysfunction and bleeding risk
• Clinical indication: Acute severe pain favors ketorolac; chronic arthritis favors etodolac

Prescribers must verify which specific NSAID is intended, as medication errors between these two drugs could result in inappropriate dosing, duration of therapy, or patient harm.